COVIDｏｆ
Part of Infections clinical trials.
This study is looking at whether giving a preventive HIV medicine called PrEP in a pediatric primary care setting can help increase its use among teens and young adults. The goal is to make it easier for young people to get PrEP and reduce their risk of HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a teen or young adult receiving care at a participating pediatric primary care site
- You are interested in or currently using PrEP for HIV prevention
- You are willing to have your care and PrEP use tracked as part of the study
- You are not currently in another PrEP implementation research study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at offering HIV prevention medicines (PrEP) to patients visiting a family planning clinic. It aims to make it easier for people to access this care alongside their regular visit.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study is testing whether starting PrEP (daily pills to prevent HIV) right away in the emergency department helps people at high risk for HIV. It aims to make it easier to start protection before you leave the hospital.
This study looks at prescribing PrEP (medication to prevent HIV) in regular doctor's offices. It may help you get easier access to prevention if you're at higher risk.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This study follows people who receive HIV care in Washington, DC and people using HIV prevention medicines (like PrEP) to understand health needs and outcomes over time. It may help improve how HIV care and prevention are delivered in local clinics.
Hear when a new PrEP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.